International Session（Symposium）3(JSGE・JGES・JSGS・JSGCS)
Thu. November 5th   14:00 - 17:00   Room 11: Portopia Hotel South Wing Topaz
IS-S3-1_G
 Advance in the treatment of IBD -the Present and the Future-
Katsuyoshi Matsuoka
Toho University Sakura Medical Center
Treatment options for IBD have increased dramatically in recent years. There is no doubt that this rapid advance was triggered by the appearance of anti-TNFα monoclonal antibody. It has made mucosal healing achievable therapeutic goal. The dramatic therapeutic effect of the anti-TNFα monoclonal antibody reagents demonstrated that mucosal inflammation could be suppressed to a completely inflammation-free state of mucosal healing by inhibiting the action of a single molecule in a complex immune response. Therefore, current IBD therapeutics are being developed with a focus on molecular targeted drugs.
Currently, four types of anti-TNFα antibody reagents has been approved in Japan. In addition, vedolizumab, an anti-α4β7 integrin antibody, ustekinumab, an anti-interleukin (IL)-12/23 p40 antibody, and tofacitinib, an oral JAK inhibitor, have also become available. Furthermore, a number of international clinical trials are being conducted. Current major therapeutic targets in IBD are 1) TNFα, 2) IL-12/23, 3) JAK, and 4) lymphocyte trafficking.
Many molecular targeted drugs are available for use in the treatment of IBD, while all of them are very expensive. It is increasingly important to properly use 5-aminosalicylic acid, steroids, and immunomodulators as basic therapies, without relying too readily on such expensive molecular targeted drugs. Furthermore, the development of biomarkers to predict the therapeutic effects of these drugs in advance is urgently needed in order to administer each agent to the most appropriate patients.
Index Term 1: Inflammatory bowel disease
Index Term 2: biologics
Page Top